Therapeutic options for human herpesvirus-8/Kaposi’s sarcoma-associated herpesvirus-related disorders

References

• Damania B, Jung JU. Comparative analysis of the transforming mechanisms of Epstein—Barr virus, Kaposi's sarcoma-associated herpesvirus and Herpesvirus saimiri. Adv. Cancer. Res. 80,51–82 (2001).
   PubMedGoogle Scholar
• Aoki Y, Tosato G. Pathogenesis and manifestations of human herpesvirus-8-associated disorders. Semin. Hematol 40(2), 143–153 (2003).
   PubMedGoogle Scholar
• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Out-patient Study Investigators. N Engl. J. Med. 338(13), 853–860. (1998).
   PubMed Web of Science ®Google Scholar
• ••Shows a dramatic impact of HAARTincluding a protease inhibitor on AIDS.
   Google Scholar
• Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994–1998: the EuroSIDA study. Lancet 356(9226), 291–296. (2000).
   PubMed Web of Science ®Google Scholar
• Nasti G, Talamini R, Antinori A, et al. AIDS-related Kaposi's sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS clinical trial group staging system in the HAART era — the Italian co-operative group on AIDS and tumors and the italian cohort of patients naive from antiretrovirals. J. Clin. Oncol 21(15), 2876–2882 (2003).
   PubMed Web of Science ®Google Scholar
• •Proposes a refinement of the original TIS staging system by the AIDS Clinical Trials Group because CD4 level does not seem to provide prognostic information.
   Google Scholar
• Scadden DT. AIDS-related malignancies. Ann. Rev. Med. 54,285–303 (2003).
   PubMed Web of Science ®Google Scholar
• Levine AM, Seneviratne L, Espina BM, et al. Evolving characteristics of AIDS-related lymphoma. Blood 96(13), 4084–4090 (2000).
   PubMedGoogle Scholar
• Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101(4), 1535–1542 (2003).
   PubMedGoogle Scholar
• Aoki Y, Jones KD, Tosato G. Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. J. Hematother. Stem. Cell Res. 9(2), 137–145 (2000).
   PubMedGoogle Scholar
• Radkov SA, Kellam P, Boshoff C. The latent nuclear antigen of kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene hras transforms primary rat cells. Nature Med. 6(10), 1121–1127 (2000).
   PubMedGoogle Scholar
• Fujimuro M, Wu FY, ApRhys C, et al. A novel viral mechanism for dysregulation of B-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nature Med. 9(3), 300–306 (2003).
   PubMedGoogle Scholar
• •Provides evidence that RNA interference is useful to suppress KSHV latent gene.
   Google Scholar
• Friborg J Jr, Kong W, Hottiger MO, Nabel GJ. Inhibition by the LANA protein of KSHV protects against cell death. Nature 402(6764), 889–894. (1999).
   PubMed Web of Science ®Google Scholar
• Swanton C, Mann DJ, Fleckenstein B, et al. Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature 390(6656), 184–187 (1997).
   PubMedGoogle Scholar
• Djerbi M, Screpanti V, Catrina AT, et al. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J. Exp. Med. 190(7), 1025–1032. (1999).
   PubMedGoogle Scholar
• Dourmishev LA, Dourmishev AL, Palmeri D, Schwartz RA, Lukac DM. Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis. Microbial. Mal. Biol. Rev. 67(2), 175–212 (2003).
   PubMedGoogle Scholar
• Aoki Y, Yarchoan R, Braun J, Iwamoto A, Tosato G. Viral and cellular cytokines in AIDS-related malignant lymphomatous effusions. Blood 96(4), 1599–1601 (2000).
   PubMedGoogle Scholar
• Aoki Y, Tosato G, Fonville TW, Pittaluga S. Serum viral interleukin-6 in AIDS-related multicentric Castleman's disease. Blood 97(8), 2526–2527 (2001).
   PubMedGoogle Scholar
• Aoki Y, Yarchoan R, Wyvill K, et al. Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders. Blood 97(7), 2173–2176 (2001).
   PubMedGoogle Scholar
• Peters M, Muller AM, Rose-John S. Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood 92(10), 3495–3504 (1998).
   PubMed Web of Science ®Google Scholar
• Aoki Y, Jaffe ES, Chang Y, et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood 93(12), 4034–4043 (1999).
   PubMedGoogle Scholar
• Aoki Y, Narazaki M, Kishimoto T, Tosato G. Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus. Blood 98(10), 3042–3049 (2001).
   PubMed Web of Science ®Google Scholar
• Murakami-Mori K, Taga T, Kishimoto T, Nakamura S. AIDS-associated Kaposi's sarcoma (KS) cells express oncostatin M (0M)-specific receptor but not leukemia inhibitory factor/OM receptor or interleukin-6 receptor. Complete block of OM-induced KS cell growth and OM binding by anti-gp130 antibodies. J. Clin. Invest. 96(3), 1319–1327 (1995).
   PubMedGoogle Scholar
• Hengge UR, Ruzicka T, Tyring SK, et al Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations and therapy. Lancet Infect. Dis. 2(5), 281–292 (2002).
   PubMedGoogle Scholar
• Cesarman E, Mesri EA, Gershengorn MC. Viral G-protein coupled receptor and Kaposi's sarcoma: a model of paracrine neoplasia? J. Exp. Med. 191(3), 417–422 (2000).
   PubMedGoogle Scholar
• Masood R, Cai J, Zheng T, et al. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc. Nad Acad. Sci. USA 94(3), 979–984 (1997).
   PubMedGoogle Scholar
• ••An important preclinical study exploringthe potential role of VEGF in AIDS-KS.
   Google Scholar
• Levine AM, Tulpule A. Clinical aspects and management of AIDS-related Kaposi's sarcoma. Eur. J. Cancer 37(10), 1288–1295 (2001).
   PubMedGoogle Scholar
• ••Excellent review of the management ofAIDS-KS.
   Google Scholar
• Reichart PA. Oral manifestations in HIV infection: fungal and bacterial infections, Kaposi's sarcoma. Med. Microbial. Immuna (Berk) 192(3), 165–169 (2003).
   PubMedGoogle Scholar
• Rohrmus B, Thoma-Greber EM, Bogner JR, Rocken M. Outlook in oral and cutaneous Kaposi's sarcoma. Lancet 356(9248), 2160 (2000).
   Google Scholar
• Aoki Y, Tosato G. Targeted inhibition of angiogenic factors in AIDS-related disorders. Curr Drug Targets Infect. Disord 3(2), 115–128 (2003).
   PubMedGoogle Scholar
• Albini A, Soldi R, Giunciuglio D, et al The angiogenesis induced by HIV-1 Tat protein is mediated by the Flk-/KDR receptor on vascular endothelial cells. Nature Med 2(12), 1371–1375. (1996).
   PubMedGoogle Scholar
• ••Provides evidence that HIV Tat canstimulate VEGFR-2.
   Google Scholar
• Aoki Y, Tosato G. HIV Tat enhances Kaposi's sarcoma-associated herpesvirus infectivity. Blood 102(11), 279a (2003).
   Google Scholar
• Ganju RK, Munshi N, Nair BC, et al Human immunodeficiency virus Tat modulates the Flk-1/KDR receptor, mitogen-activated protein kinases and components of focal adhesion in Kaposi's sarcoma cells. J. ViroL 72(7), 6131–6137 (1998).
   PubMedGoogle Scholar
• Lafrenie RI, Wahl LM, Epstein JS, et al HIV-1-Tat modulates the function of monocytes and alters their interactions with microvessel endothelial cells. A mechanism of HIV pathogenesis. J. Immund 156(4), 1638–1645 (1996).
   PubMedGoogle Scholar
• Lafrenie RI, Wahl LM, Epstein JS, Yamada KM, Dhawan S. Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression. J Immund 159(8), 4077–4083 (1997).
   PubMedGoogle Scholar
• Little RF, Gutierrez M, Jaffe ES, et al HIV-associated non-Hodgkin lymphoma: incidence, presentation and prognosis. JAMA 285(14), 1880–1885 (2001).
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of AIDS-NHL.
   Google Scholar
• Carbone A, Gloghini A, Larocca LM, et al Expression profile of MUM1/IRF4, BCL-6 and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood 97(3), 744-751(2001).
   PubMedGoogle Scholar
• Simonelli C, Spina M, Cinelli R, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J. Clin. OncoL 21(21), 3948–3954 (2003).
   PubMed Web of Science ®Google Scholar
• Nador RG, Cesarman E, Chadburn A, et al Primary effusion lymphoma: a distinct dinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 88(2), 645–656 (1996).
   PubMed Web of Science ®Google Scholar
• Aoki Y, Tosato G. Vascular endothelial growth factor/vascular permeability factor in the pathogenesis of primary effusion lymphomas. Leuk. Lymphoma 41(3–4), 229–237 (2001).
   Google Scholar
• Klein U, Gloghini A, Gaidano G, et al. Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 101(10), 4115–4121 (2003).
   PubMedGoogle Scholar
• Jenner RG, Maillard K, Cattini N, et al. Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile. Proc. Nad Acad Sci. USA 100(18), 10399–10404 (2003).
   PubMedGoogle Scholar
• Aoki Y, Tosato G. Viral and cellular cytokines as therapeutic targets in AIDS-related lymphoproliferative disorders. Curr. Drug Targets Cardiovasc. Haematol. Disord. 3(1), 81–96 (2003).
   Google Scholar
• Jones KD, Aoki Y, Chang Y, et al. Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells. Blood 94(8), 2871–2879 (1999).
   PubMed Web of Science ®Google Scholar
• Aoki Y, Tosato G. Role of vascular endothelial growth factor/vascular permeability factor in the pathogenesis of Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphomas. Blood 94(12), 4247–4254 (1999).
   PubMedGoogle Scholar
• Aoki Y, Tosato G, Nambu Y, Iwamoto A, Yarchoan R. Detection of vascular endothelial growth factor in AIDS-related primary effusion lymphomas. Blood 95(3), 1109–1110 (2000).
   Google Scholar
• Weisenburger DD. Multicentric angiofollicular lymph node hyperplasia. Pathology of the spleen. Am. J. Surg Pathol. 12(3), 176–181 (1988).
   PubMedGoogle Scholar
• Oksenhendler E, Duarte M, Soulier J, et al Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS 10(1), 61–67 (1996).
   Google Scholar
• •• A comprehensive study of HIV-related MCD.
   Google Scholar
• Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86(4), 1276–1280 (1995).
   PubMed Web of Science ®Google Scholar
• Katano H, Sato Y, Kurata T, Mod S, Sata T Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma and multicentric Castleman's disease. Virology 269(2), 335–344 (2000).
   PubMedGoogle Scholar
• ••Demonstrates the difference in KSHV gene expression profile between KS, PEL and MCD.
   Google Scholar
• Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 95(4), 1406–1412 (2000).
   PubMed Web of Science ®Google Scholar
• Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 99(7), 2331–2336 (2002).
   PubMed Web of Science ®Google Scholar
• Engels EA, Pittaluga S, Whitby D, et al. Immunoblastic lymphoma in persons with AIDS-Associated kaposi's sarcoma: a role for kaposi's sarcoma-associated herpesvirus. Mod Pathol. 16(5), 424–429 (2003).
   PubMedGoogle Scholar
• Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10 and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Blood 96(6), 2069–2073 (2000).
   PubMed Web of Science ®Google Scholar
• Corbellino M, Bestetti G, Scalamogna C, et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 98(12), 3473–3475 (2001).
   PubMed Web of Science ®Google Scholar
• Schulz TF. KSHV/HHV8-associated lymphoproliferations in the AIDS setting. Eur. J. Cancer 37(10), 1217–1226 (2001).
   Google Scholar
• Nishimoto N, Sasai M, Shima Y, et al Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95(1), 56–61 (2000).
   PubMed Web of Science ®Google Scholar
• Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response and staging criteria. AIDS Clinical Trials Group Oncology Committee. J. Clin. Oncol. 7(9), 1201–1207 (1989).
   PubMed Web of Science ®Google Scholar
• Krown SE, Testa MA, Huang J. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J. Clin. Oncol. 15(9), 3085–3092 (1997).
   PubMed Web of Science ®Google Scholar
• ••Prospective validation of the AIDS Clinical Trials Group TIS classification that predicts survival in patients with AIDS-associated KS.
   Google Scholar
• Cattelan AM, Calabro ML, Aversa SM, et al. Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. Eur. J. Cancer 35(13), 1809–1815 (1999).
   PubMedGoogle Scholar
• Lebbe C, Blum L, Pellet C, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS 12(7), F45—F49 (1998).
   PubMedGoogle Scholar
• DuPont C, Vasseur E, Beauchet A, et al. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre &information et de soins de Fimmunodeficience humaine. AIDS 14(8), 987–993 (2000).
   PubMedGoogle Scholar
• Dupin N, Rubin De Cervens V, Gorin I, et al. The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma. Br. J. Dermatol.140(5), 875–881 (1999).
   Google Scholar
• Gill J, Bourboulia D, Wilkinson J, et al. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma-associated herpesvirus infection in patients with and without Kaposi sarcoma. J. Acquir. Immune. Defic. Syndr. 31(4), 384–390 (2002).
   PubMedGoogle Scholar
• Nasti G, Martellotta F, Berretta M, et al. Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer 98(11), 2440–2446 (2003).
   PubMedGoogle Scholar
• Sgadari C, Barillari G, Toschi E, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nature Med. 8(3), 225–232 (2002).
   PubMed Web of Science ®Google Scholar
• Pati S, Pelser CB, Dufraine J, et al. Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi's sarcoma. Blood 99(10), 3771–3779 (2002).
   PubMed Web of Science ®Google Scholar
• Wensing AM, Boucher CA. Worldwide transmission of drug-resistant HIV. AIDS Rev. 5(3), 140–155 (2003).
   PubMedGoogle Scholar
• Chen RY, Westfall AO, Raper JL, et al. Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice. AIDS Res. Hum. Retroviruses 18(13), 909–916 (2002).
   PubMedGoogle Scholar
• Oksenhendler E, Clauvel JP, Jouveshomme S, Davi F, Mansour G. Complete remission of a primary effusion lymphoma with antiretroviral therapy. Am. J. Hematol. 57(3), 266 (1998).
   Google Scholar
• Aaron L, Lidove O, Yousry C, et al. Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: the impact of highly active antiretroviral therapy. Clin. Infect. Dis. 35(7), 880–882 (2002).
   PubMed Web of Science ®Google Scholar
• Marcelin AG, Aaron L, Mateus C, et al. Rituximab therapy for HIV-associated Castleman disease. Blood 102(8), 2786–2788 (2003).
   PubMed Web of Science ®Google Scholar
• Hocqueloux L, Agbalika F, Oksenhendler E, Molina JM. Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS 15(2), 280–282 (2001).
   PubMed Web of Science ®Google Scholar
• Spina M, Gaidano G, Carbone A, Capello D, Tirelli U. Highly active antiretroviral therapy in human herpesvirus-8-related body-cavity-based lymphoma. AIDS 12(8), 955–956 (1998).
   PubMedGoogle Scholar
• Dupin N, Krivine A, Calvez V, et al. No effect of protease inhibitor on clinical and virological evolution of Castleman's disease in an HIV-1-infected patient. AIDS 11(11), 1400–1401 (1997).
   PubMedGoogle Scholar
• Tappero J, Berger TG, Kaplan LD, Volberding PA, Kahn JO. Cryotherapy for cutaneous Kaposi's sarcoma (KS) associated with acquired immune deficiency syndrome (AIDS): a Phase II trial. J Acquir. Immune Defic. Syndr. 4(9), 839–846 (1991).
   PubMed Web of Science ®Google Scholar
• Karrer S, Szeimies RM, Hohenleutner U, Landthaler M. Role of lasers and photodynamic therapy in the treatment of cutaneous malignancy. Am. J. Clin. Dermatol. 2(4), 229–237 (2001).
   PubMedGoogle Scholar
• Walmsley S, Northfelt DW, Melosky B, et al. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J. Acquir. Immune Defic. Syndr. 22(3), 235–246 (1999).
   PubMedGoogle Scholar
• Flaitz CM, Nichols CM, Hicks MJ. Role of intralesional vinblastine administration in treatment of intraoral Kaposi's sarcoma in AIDS. Eu. J. Cancer B. Oral. Oncol. 31B(4), 280–285 (1995).
   PubMedGoogle Scholar
• Kirova YM, Belembaogo E, Frikha H, et al. Radiotherapy in the management of epidemic Kaposi's sarcoma: a retrospective study of 643 cases. Radiother. Oncol 46(1), 19–22 (1998).
   PubMed Web of Science ®Google Scholar
• Cattelan AM, Trevenzoli M, Aversa SM. Recent advances in the treatment of AIDS-related Kaposi's sarcoma. Am. J. Clin. Dermatol 3(7), 451–462 (2002).
   PubMedGoogle Scholar
• Gill PS, Wernz J, Scadden DT, et al. Randomized Phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin and vincristine in AIDS-related Kaposi's sarcoma. J. Clin. Oncol 14(8), 2353–2364 (1996).
   PubMed Web of Science ®Google Scholar
• Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized Phase III clinical trial. J. Clin. Oncol. 16(7), 2445–2451 (1998).
   PubMed Web of Science ®Google Scholar
• Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J. Clin. Oncol 16(2), 683–691 (1998).
   PubMed Web of Science ®Google Scholar
• Gill PS, Tulpule A, Espina BM, et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. J. Clin. Oncol 17(6), 1876–1883 (1999).
   PubMedGoogle Scholar
• Monini P, Carlini F, Sturzl M, et al. Interferon a inhibits human herpesvirus 8 (HHV-8) reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured peripheral blood mononuclear cells. J Viral. 73(5), 4029–4041 (1999).
   PubMedGoogle Scholar
• Shepherd FA, Beaulieu R, Gelmon K, et al. Prospective randomized trial of two dose levels of interferon-a with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV clinical trials network study. J. Clin. Oncol. 16(5), 1736–1742 (1998).
   PubMedGoogle Scholar
• Krown SE, Li P, Von Roenn JH, Paredes J, Huang J, Testa MA. Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized Phase II AIDS clinical trials group study. J. Interferon Cytokine Res. 22(3), 295–303 (2002).
   PubMedGoogle Scholar
• Krown SE. Interferon-a: evolving therapy for AIDS-associated Kaposi's sarcoma. J. Interferon Cytokine Res. 18(4), 209–214 (1998).
   PubMedGoogle Scholar
• Nagpal S, Cai J, Zheng T, et al Retinoid antagonism of NF-IL6: insight into the mechanism of antiproliferative effects of retinoids in Kaposi's sarcoma. Mal Cell Bid 17(7), 4159–4168 (1997).
   PubMedGoogle Scholar
• Miles SA, Dezube BJ, Lee JY, et al Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma. AIDS 16(3), 421–429. (2002).
   PubMedGoogle Scholar
• Aboulafia DM, Norris D, Henry D, et al 9-cis-retinoic acid capsules in the treatment of AIDS-related Kaposi sarcoma: results of a Phase II multicenter clinical trial. Arch. Dermatol 139(2), 178–186 (2003).
   PubMedGoogle Scholar
• Lee FC, Merchant SH. Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide. Am. J. Hematol 73(1), 48–53 (2003).
   PubMedGoogle Scholar
• Liberopoulos E, Tolis C, Bai M, et al Successful treatment of human immunodeficiency virus-related Castleman's disease: a case report and literature review. Oncology 65(2), 182–186 (2003).
   PubMedGoogle Scholar
• Chronowski GM, Ha CS, Wilder RB, et al Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 92(3), 670–676 (2001).
   PubMed Web of Science ®Google Scholar
• Morlat P, Dequae-Merchadou L, Dabis F, et al Splenectomy and prognosis of HIV infection. Group d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA). AIDS 10(10), 1170–1172 (1996).
   PubMedGoogle Scholar
• Komanduri KV, Luce JA, McGrath MS, Herndier BG, Ng VL. The natural history and molecular heterogeneity of HIV-associated primary malignant lymphomatous effusions. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol 13(3), 215–226 (1996).
   PubMedGoogle Scholar
• Valencia ME, Martinez P, Moreno V, Laguna F, Lahoz JG. AIDS-related body cavity-based lymphomas, herpesvirus-8 and HIV infection: a study of seven cases. AIDS 13(18), 2603–2605 (1999).
   PubMedGoogle Scholar
• Ansari MQ, Dawson DB, Nador R, et al Primary body cavity-based AIDS-related lymphomas. Am. J. Clin. Pathol 105(2), 221–229 (1996).
   PubMedGoogle Scholar
• Boulanger E, Daniel MT, Agbalika F, Oksenhendler E. Combined chemotherapy including high-dose methotrexate in KSHV/HHV8-associated primary effusion lymphoma. Am. J. Hematol 73(3), 143–148 (2003).
   PubMed Web of Science ®Google Scholar
• Kumari P, Schechter GP, Saini N, Benator DA. Successful treatment of human immunodeficiency virus-related Castleman's disease with interferon-a. Clin. Infect. Dis. 31(2), 602–604 (2000).
   PubMed Web of Science ®Google Scholar
• Medveczky MM, Horvath E, Lund T, Medveczky PG. In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus. AIDS 11(11), 1327–1332 (1997).
   Google Scholar
• Martin DF, Kuppermann BD, Wolitz RA, et al Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J. Med 340(14), 1063–1070 (1999).
   PubMedGoogle Scholar
• Mazzi R, Parisi SG, Sarmati L, et al Efficacy of cidofovir on human herpesvirus 8 viraemia and Kaposi's sarcoma progression in two patients with AIDS. AIDS 15(15), 2061–2062 (2001).
   PubMedGoogle Scholar
• Pastore RD, Chadburn A, Kripas C, Schattner EJ. Novel association of haemophagocytic syndrome with Kaposi's sarcoma-associated herpesvirus-related primary effusion lymphoma. Br J. Haematol 111(4), 1112–1115 (2000).
   PubMedGoogle Scholar
• Casper C, Nichols WG, Huang ML, Corey L, Wald A. Remission of HHV-8 and HIV-associated multicentric Castleman's disease with ganciclovir treatment. Blood 103(5) 1632–1634 (2003).
   PubMedGoogle Scholar
• Little RF, Merced-Galindez F, Staskus K, et al A pilot study of cidofovir in patients with kaposi sarcoma. J Infect. Dis. 187(1), 149–153. (2003).
   PubMedGoogle Scholar
• Senanayake S, Kelly J, Lloyd A, et al Multicentric Castleman's disease treated with antivirals and immunosuppressants. j Med Viral. 71(3), 399–403 (2003).
   PubMedGoogle Scholar
• Masood R, Nagpal S, Zheng T, et al Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist. Blood 96(9), 3188-3194(2000).
   PubMedGoogle Scholar
• Krown SE. Therapy of AIDS-associated Kaposi's sarcoma: targeting pathogenetic mechanisms. Hematol Oncol Clin. North Am. 17(3), 763–783 (2003).
   PubMedGoogle Scholar
• ••Excellent review of ongoing clinical trials forAIDS-KS.
   Google Scholar
• Little RF, Wyvill KM, Pluda JM, et al Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin. Oncol 18(13), 2593–2602. (2000).
   PubMed Web of Science ®Google Scholar
• Dezube BJ, Von Roenn JH, Holden-Wiltse J, et al Fumagillin analog in the treatment of Kaposi's sarcoma: a Phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J Clin. Oncol 16(4), 1444–1449 (1998).
   PubMedGoogle Scholar
• Cianfrocca M, Cooley TP, Lee JY, et al Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a Phase I AIDS malignancy consortium study. Clin. Oncol 20(1), 153–159 (2002).
   Google Scholar
• Levine AM, Quinn DI, Gorospe G, et al. Phase I trial of vascular endothelial growth factor-antisense (VEGF-AS, Veglin) in relapsed and refractory malignancy. Blood 102(11), 123a (2003).
   Google Scholar
• Tulpule A, Scadden DT, Espina BM, et al. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 18(4), 716–723 (2000).
   PubMedGoogle Scholar
• Arasteh K, Hannah A. The role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma. Oncologist 5\(Suppl. 1), 28–31 (2000).
   PubMedGoogle Scholar
• Van der Kolk LE, Baars JW, Prins MH, van Oers MH. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 100(6), 2257–2259 (2002).
   PubMed Web of Science ®Google Scholar
• Montaner S, Sodhi A, Molinolo A, et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 3(1), 23–36 (2003).
   PubMed Web of Science ®Google Scholar
• O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109(Suppl.), S121—S131 (2002).
   Google Scholar
• Altieri DC. Validating survivin as a cancer therapeutic target. Nature Rev. Cancer 3(1), 46–54. (2003).
   PubMed Web of Science ®Google Scholar